Lars Savendahl (Lars Sävendahl)

Years Active: 2020-2023
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Lars Savendahl, Tadej Battelino, Michael Højby Rasmussen, Meryl Brod, Sebastian Röhrich, Paul Saenger, Reiko Horikawa
Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety and Treatment/Disease Burden Results from REAL 3. The Journal of clinical endocrinology and metabolism (2023)
Lars Savendahl, Tadej Battelino, Michael Højby Rasmussen, Meryl Brod, Paul Saenger, Reiko Horikawa
Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3. The Journal of clinical endocrinology and metabolism 107 (5) (2022)
Lars Savendahl, Michel Polak, Philippe Backeljauw, Joanne C Blair, Bradley S Miller, Tilman R Rohrer, Anita Hokken-Koelega, Alberto Pietropoli, Nicky Kelepouris, Judith Ross
Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER. The Journal of clinical endocrinology and metabolism 106 (6) (2021)
Dieter Haffner, Francesco Emma, Deborah M Eastwood, Martin Biosse Duplan, Justine Bacchetta, Dirk Schnabel, Philippe Wicart, Detlef Bockenhauer, Fernando Santos, Elena Levtchenko, Pol Harvengt, Martha Kirchhoff, Federico Di Rocco, Catherine Chaussain, Maria Louisa Brandi, Lars Savendahl, Karine Briot, Peter Kamenicky, Lars Rejnmark, Agnès Linglart
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nature reviews. Nephrology 15 (7) (2020)

Lars Savendahl.css-eqlu8i{font-size:small;padding-left:4px;} (Lars Sävendahl)